BTIG Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $20
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
BTIG analyst Thomas Shrader maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and lowers the price target from $23 to $20.
BTIG analyst Thomas Shrader maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and lowers the price target from $23 to $20.